Menu Search
Equities

StageZero Life Sciences Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
61N1:STU

StageZero Life Sciences Ltd

Actions
  • Price (EUR)0.0155
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 09 2024.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

StageZero Life Sciences, Ltd. is an integrated healthcare company focused on enhancing the early detection and management of cancer and chronic diseases through advanced molecular diagnostics and clinical interventions. It is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The Company offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.

  • Revenue in CAD (TTM)--
  • Net income in CAD--
  • Incorporated1997
  • Employees40.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.